Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024
STAFFORD, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq:GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company’s directors, officers, and existing pre-IPO investors to December 31, 2024 which is approximately 51 months from date of the Company’s IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company’s common stock unless otherwise modified by the Board of Directors.
Related news for (GLSI)
- Greenwich LifeSciences Provides Global Update on FLAMINGO-01
- Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
- Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
- Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
- Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01